Vera Therapeutics' dual BAFF/APRIL inhibitor reduced proteinuria 45.7% at week 36 in the NEJM-published ORIGIN 3 trial, with an FDA accelerated-approval decision due July 7.
NASA assigned Randy Bresnik, Luca Parmitano, Andre Douglas, and Frank Rubio to Artemis III, a 2027 Earth-orbit test flight to practice docking with SpaceX and Blue Origin landers.
The Fifth Circuit stayed an injunction against Texas SB 2420, letting the App Store Accountability Act take effect June 4 as Apple rolled out age-assurance rules.
Microsoft unveiled seven proprietary MAI models led by the 35B-active reasoning model MAI-Thinking-1, all trained from scratch without distillation as it reduces its dependence on OpenAI.
Collectibles became GameStop's largest segment in Q1 fiscal 2026, but $268.4 million of its record net income came from an unrealized gain on eBay-linked options.
CFS released five peer-reviewed papers with 58 co-authors detailing the physics basis for ARC, its planned 400 MW fusion plant.
The maintenance release folds in fixes from Scala's first external security audit, which found no critical or major issues but flagged a stored XSS in Scaladoc and an infinite loop in TASTy parsing.
A logic flaw in Check Point's deprecated IKEv1 certificate validation let attackers bypass VPN authentication. CISA added it to KEV with a June 11 deadline.
UBTECH, which sold 1,079 industrial humanoids in 2025, has launched a consumer brand, UWORLD, and opened JD.com preorders for the U1 ahead of a June 30 reveal.
Eli Lilly presented phase 3 results for retatrutide at ADA 2026 on June 6, showing 28.3% mean weight loss at 80 weeks in obesity and a companion diabetes trial published in The Lancet.
A Center for Democracy & Technology study built a taxonomy of 37 manipulative design patterns it found across major AI chatbots and companion apps.
The vendor-neutral foundation will partner with FinOps to extend the FOCUS billing spec to AI token spend, backed by 12 enterprises.